Gilead Sciences nears $2B acquisition of autoimmune specialist Ouro Medicines
Gilead Sciences (NYSE:GILD) is nearing a definitive agreement to acquire Ouro Medicines, a biotechnology company focused on chronic immune-mediated diseases, for a total consideration of up to $2 billion.











